Vitae Pharmaceuticals Inc. (NASDAQ:VTAE)’s share price was down 3.6% during mid-day trading on Thursday . The company traded as low as $10.91 and last traded at $10.96, with a volume of 53,686 shares. The stock had previously closed at $11.37.

Several equities analysts recently weighed in on VTAE shares. Wells Fargo & Co. reiterated a “buy” rating on shares of Vitae Pharmaceuticals in a research report on Friday, June 10th. Zacks Investment Research upgraded Vitae Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.25 target price on the stock in a research report on Thursday, April 7th. BMO Capital Markets started coverage on Vitae Pharmaceuticals in a research report on Monday, April 11th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $23.00 target price on shares of Vitae Pharmaceuticals in a research report on Wednesday, May 25th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $16.65.

The company’s 50-day moving average is $10.50 and its 200 day moving average is $8.80. The firm’s market cap is $318.69 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. The business had revenue of $0.05 million for the quarter. The company’s quarterly revenue was down 66.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.47) earnings per share. Analysts predict that Vitae Pharmaceuticals Inc. will post ($1.74) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP purchased a new position in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned about 0.34% of Vitae Pharmaceuticals as of its most recent SEC filing.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.